{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:24:45Z","timestamp":1774542285339,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,11]]},"DOI":"10.7759\/cureus.16316","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:19:10Z","timestamp":1626049150000},"source":"Crossref","is-referenced-by-count":4,"title":["Myasthenia Gravis as an Immune-Mediated Side Effect of Checkpoint Inhibitors"],"prefix":"10.7759","author":[{"given":"Caio T","family":"Heleno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico A","family":"Gotera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.48.suppl_5.23s","article-title":"Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome","volume":"48","author":"Lennon VA","year":"1997","unstructured":"Lennon VA. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology. 1997, 48:23S-27S. 10.1212\/wnl.48.suppl_5.23s","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.036","article-title":"Antibodies in myasthenia gravis and related disorders","volume":"998","author":"Vincent A","year":"2003","unstructured":"Vincent A, McConville J, Farrugia ME, et al.. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci. 2003, 998:324-35. 10.1196\/annals.1254.036","journal-title":"Ann N Y Acad Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan KH","year":"2007","unstructured":"Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007, 36:651-8. 10.1002\/mus.20854","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000415","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"22","author":"Nicolle MW","year":"2016","unstructured":"Nicolle MW. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum. 2016, 22:1978-2005. 10.1212\/CON.0000000000000415","journal-title":"Continuum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.010","article-title":"Diagnosis of myasthenia gravis","volume":"36","author":"Pasnoor M","year":"2018","unstructured":"Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ. Diagnosis of myasthenia gravis. Neurol Clin. 2018, 36:261-74. 10.1016\/j.ncl.2018.01.010","journal-title":"Neurol Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom JM","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976, 26:1054-9. 10.1212\/wnl.26.11.1054","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent A","year":"1985","unstructured":"Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985, 48:1246-52. 10.1136\/jnnp.48.12.1246","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard FM Jr","year":"1987","unstructured":"Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987, 505:526-38. 10.1111\/j.1749-6632.1987.tb51321.x","journal-title":"Ann N Y Acad Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63489-myasthenia-gravis-as-an-immune-mediated-side-effect-of-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:16Z","timestamp":1707506776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63489-myasthenia-gravis-as-an-immune-mediated-side-effect-of-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,11]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.16316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,11]]}}}